CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-10 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −50,000 | $7.48 | $374K | 758,738 |
| 2024-07-10 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −50,000 | 6,276,700 | ||
| 2024-07-10 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,331,593 |
| 2024-07-10 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $7.24 | $109K | 1,316,593 |
| 2024-07-10 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 652,635 | ||
| 2024-07-09 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,307,218 |
| 2024-07-09 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $7.32 | $110K | 1,292,218 |
| 2024-07-09 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 692,010 | ||
| 2024-07-09 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $7.32 | $84K | 7,167,110 |
| 2024-07-01 | Li Dean Y Director | Grant or award | +1,592 | 73,778 | ||
| 2024-07-01 | Dar Zavain Director | Grant or award | +1,843 | 103,996 | ||
| 2024-07-01 | Burrell Terry-Ann Director | Grant or award | +1,843 | 71,254 | ||
| 2024-07-01 | Borgeson Blake Director | Grant or award | +1,441 | 7,178,557 | ||
| 2024-06-27 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +6,000 | $1.06 | $6K | 541,457 |
| 2024-06-27 | Marriott Tina President and COO | Sale 10b5-1 | −6,000 | $7.22 | $43K | 535,457 |
| 2024-06-27 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −6,000 | 476,000 | ||
| 2024-06-25 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $9.51 | $109K | 7,177,116 |
| 2024-06-14 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,282,843 |
| 2024-06-14 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $9.27 | $139K | 1,267,843 |
| 2024-06-14 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 731,385 |
Page 18 of 41 · 805 trades